MEDI 8897

Drug Profile

MEDI 8897

Alternative Names: Anti-RSV mAb D25; Anti-RSV MAb-YTE; MEDI-8897; Respiratory syncytial virus monoclonal antibody D25; SP 0232

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AIMM Therapeutics
  • Developer MedImmune
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Respiratory syncytial virus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In volunteers) in USA (IM)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In volunteers) in USA (IV)
  • 08 Oct 2017 Safety and pharmacokinetics data from a phase-I/II trial in Respiratory syncytial virus infections presented at the IDWeek 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top